Fast Five Quiz: Molecular and Biomarker Analysis in Non–Small Cell Lung Cancer (NSCLC)

Daniel S. Schwartz, MD


January 28, 2022

Predictive/actionable NSCLC biomarkers are associated with specific targeted therapy/therapies that has/have been shown to improve outcomes in patients with the predictive biomarker. By contrast, prognostic biomarkers are indicative of patient survival independent of the treatment received because they indicate innate tumor aggressiveness, as in the case of KRAS mutations. Broad molecular profiling systems may be used to simultaneously test for multiple biomarkers.

Learn more about molecular testing in NSCLC.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.